Last reviewed · How we verify
Envlo Tablet
At a glance
| Generic name | Envlo Tablet |
|---|---|
| Also known as | Enavogliflozin 0.3mg |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
- Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus
- Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
- The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Envlo Tablet CI brief — competitive landscape report
- Envlo Tablet updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI